Loading clinical trials...
Loading clinical trials...
Population Pharmacokinetics and Pharmacodynamics of Standard First Line Anti-TB Versus Atorvastatin-Containing Regimens in the Treatment of Pulmonary Tuberculosis: A Sub-study of the ATORTUB Phase 2C Randomized Controlled Trial (ATORTUB popPK-PD Study)
Conditions
Interventions
Atorvastatin 20 mg
Atorvastatin 40 mg
+2 more
Locations
3
Nigeria
National Tuberculosis and Leprosy Training Centre, Saye
Zaria, Kaduna State, Nigeria
Federal Teaching Hospital
Katsina, Katsina State, Nigeria
Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife, Osun state, Nigeria
Ile-Ife, Osun State, Nigeria
Start Date
January 3, 2026
Primary Completion Date
March 30, 2027
Completion Date
March 30, 2028
Last Updated
January 23, 2026
Lead Sponsor
Obafemi Awolowo University Teaching Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions